Newly reported laboratory results suggest that certain naturally-occurring immune system cells could one day serve as a treatment for multiple myeloma.

The results also suggest that therapies based on these cells may be made more effective when combined with a drug already used to treat myeloma.

Invariant natural killer T cells – or “iNKT" cells – are antitumor immune system cells. In multiple myeloma patients, iNKT cells are often defective or in short supply.

Researchers affiliated with Harvard University decided to test whether iNKT cells display antitumor activity against …

The health care system in England and Wales may soon stop funding the use of the drug Revlimid (lenalidomide) to treat multiple myeloma.

The agency responsible for controlling health care costs in those countries has issued a preliminary ruling that treating myeloma with Revlimid is not cost effective.

The agency – the National Institute for Health and Clinical Excellence (NICE) – admits that the drug is clinically effective. The once-a-day capsule has been shown to extend the lives of myeloma patients by nearly three years. As …